The U.S. District Court for the Northern District of Mississippi has entered a consent decree prohibiting Delta Pharma from manufacturing or distributing compounded drugs until they comply with the Federal Food, Drug, and Cosmetic Act and FDA regulations, the Food and Drug Administration announced Friday. The company is registered as an outsourcing facility under Section 503B of the Act. "That legislation envisioned an important role for outsourcing facilities to help supply providers with compounded medicines, but it also required that these firms meet good manufacturing practice requirements,” said FDA Commissioner Scott Gottlieb, M.D. “When we find outsourcing facilities that continue to violate the law by not adhering to these manufacturing requirements, and put patients at risk, we’re going to hold them accountable under the law. At the same time, we’re also pursuing new policy steps to help make it more feasible for compounders to meet the requirements of becoming an outsourcing facility.”

Related News Articles

Headline
The Food and Drug Administration Friday released draft guidance on how drug developers can apply for the agency’s Competitive Generic Therapies designation.
Headline
The AHA and Federation of American Hospitals today urged the U.S. Supreme Court to review a federal appeals court decision that allows False Claims Act…
Headline
The House Energy and Commerce Health Subcommittee today held a hearing on legislation to roll back changes to the Affordable Care Act by the Trump…
Headline
The AHA yesterday urged Sens. Bill Cassidy, R-La., and Dick Durbin, D-Ill., not to re-introduce legislation that would establish rehabilitation innovation…
Headline
The AHA today expressed support for the Resident Physician Shortage Reduction Act, legislation that would add 15,000 Medicare-funded residency positions over…
Headline
Reps.